All In Biotech

Drug Trial Radar · NCT05378893

A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624

A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-and-Multiple-Ascending Subcutaneous Doses of DR10624

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

153

Actual

Start

Jun 22, 2022

Primary completion

Oct 10, 2024

Study completion Jan 31, 2025

Sponsor

Sponsor type
Industry
First posted
May 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending doses of DR10624 via subcutaneous (SubQ) injection in a randomized, placebo-controlled, double-blind study.

Conditions

  • Healthy, Obesity, Metabolically

Interventions

  • DR10624 for injectionDrug

    administered via subcutaneous injection

  • PlaceboDrug

    administered via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the Safety and TolerabilityTime frame: Baseline through Day 29 (Part 1 & Part 3); Pre-final dose on Day 78 through Day 106 (Part 2)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research

    Christchurch, Canterbury, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.